35 results
8-K
EX-99.1
ABSI
Absci Corp
4 Oct 22
Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer
4:09pm
of Directors to Absci’s Executive Leadership team
With a proven track record advancing drugs from discovery to market, Dr. Busch brings world-class R&D expertise … the appointment of Andreas Busch, PhD, as Chief Innovation Officer, where he will be responsible for leading R&D, technical operations, and driving both Absci’s
8-K
EX-99.2
ABSI
Absci Corp
14 Nov 23
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
4:40pm
is eligible to receive up to approximately $650 million in upfront fees, R&D, and post-approval milestone payments across the two programs if all milestones … challenging targets facing high unmet medical need,” said Almirall Executive VP of R&D and CSO Dr. Karl Ziegelbauer. “Our partnership underlines Almirall’s
8-K
EX-99.1
ABSI
Absci Corp
9 Nov 22
Absci Reports Third Quarter 2022 Financial Results
9:18am
and significant industry interest. Further, we welcomed Dr. Andreas Busch to Absci as Chief Innovation Officer, bringing world-class R&D expertise to our executive … Creation™ platform will accelerate drug development timelines and decrease attrition in early R&D.
Continued to strengthen executive leadership team
8-K
EX-99.1
ABSI
Absci Corp
14 Nov 23
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
4:40pm
million in upfront fees, R&D, and post-approval milestone payments across the two programs if all milestones are successfully completed.
Unveiled AI … by lower laboratory operational costs, increased efficiencies, and a prioritized focus within Absci's R&D efforts.
Selling, general
8-K
ABSI
Absci Corp
20 Dec 23
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
8:30am
titled “Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline.” A copy of the press release
8-K
wev8q 6apt3sptbcpna
7 Dec 23
Departure of Directors or Certain Officers
8:30am
8-K
EX-99.1
hef9ggttz07t5kfeamq
8 Jan 24
Absci Corporation 2024 All Rights Reserved 42ND JP Morgan Healthcare Conference
7:08am
8-K
EX-99.1
yr826anozp4 zh1
4 Dec 23
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
7:31am
8-K
EX-99.1
dw02f 4bkdf36mj
20 Dec 23
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
8:30am
8-K
EX-99.1
komd25ho
11 Aug 22
Absci Reports Second Quarter 2022 Financial Results and Business Update
8:33am
8-K
EX-99.1
yh9tsahmcf252arx a7z
22 Mar 22
Absci Reports Full Year 2021 Financial and Operating Results
4:07pm
8-K
EX-99.1
bk46a5gaj990km0
14 Aug 23
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
8:13am
8-K
EX-99.1
85pf7ocdv 6u
21 Mar 24
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
7:31am
8-K
dxan345azgkjm2yqxl
27 Feb 24
Results of Operations and Financial Condition
4:45pm
DRS/A
EX-10.11
z37pm7j 4l
16 Jun 21
Draft registration statement (amended)
12:00am
S-1
EX-10.11
wkryh59a 1w9
30 Jun 21
IPO registration
3:20pm
DEF 14A
qzxgql
26 Apr 22
Definitive proxy
4:39pm